Waverly Advisors LLC Purchases 5,800 Shares of AbbVie Inc. $ABBV

Posted by Don Miller on Jul 26th, 2026

Waverly Advisors LLC boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 224,676 shares of the company’s stock after purchasing an additional 5,800 shares during the period. Waverly Advisors LLC’s holdings in AbbVie were worth $48,865,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of AbbVie during the fourth quarter worth about $5,865,055,000. Wellington Management Group LLP raised its holdings in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the last quarter. Capital World Investors boosted its position in AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after buying an additional 6,736,161 shares during the period. Cardano Risk Management B.V. boosted its position in AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after buying an additional 4,908,260 shares during the period. Finally, Geode Capital Management LLC grew its holdings in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 0.8%

ABBV stock opened at $259.10 on Friday. The firm has a market cap of $457.78 billion, a price-to-earnings ratio of 127.64, a PEG ratio of 0.86 and a beta of 0.30. AbbVie Inc. has a 12-month low of $187.62 and a 12-month high of $261.64. The company’s fifty day simple moving average is $234.57 and its 200 day simple moving average is $222.86.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the prior year, the firm posted $2.46 earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. Research analysts expect that AbbVie Inc. will post 14.18 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie is expected to report earnings next week, and several market write-ups highlight the stock as a potential winner if results or guidance beat expectations. Analysts also noted the shares may have room to rise if the company delivers on revenue and profit growth. AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release
Positive Sentiment: Canaccord Genuity reiterated a constructive view on AbbVie, with a report saying the stock price is expected to rise, which may be helping sentiment around the name. AbbVie (NYSE:ABBV) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
Neutral Sentiment: AbbVie also announced progress on early-stage pipeline work for nacresertib and ABBV-313, but these updates are preliminary and are unlikely to move the stock as much as late-stage clinical data. AbbVie Advances Nacresertib With Key Drug–Drug Interaction Study AbbVie’s ABBV-313 Phase 1 Trial: What Early Safety Work Means for Investors
Negative Sentiment: AbbVie and Genmab said the Phase 3 EPCORE DLBCL-1 trial for lymphoma drug epcoritamab missed its sole U.S. primary endpoint, a setback that could weigh on sentiment toward the company’s oncology pipeline. Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Analyst Upgrades and Downgrades

ABBV has been the subject of several recent research reports. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. HSBC reiterated a “buy” rating and set a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. Morgan Stanley increased their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Canaccord Genuity Group raised their target price on AbbVie from $273.00 to $282.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $268.10.

Check Out Our Latest Research Report on AbbVie

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.